Navigation Links
Cardiac Science to Present at the Roth 21st Annual OC Growth Stock Conference

BOTHELL, Wash., Feb. 17 /PRNewswire-FirstCall/ -- Cardiac Science (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, today announced today that it will present at the Roth 21st Annual OC Growth Stock Conference at the Ritz Carlton Laguna Nigel. John Hinson, president and chief executive officer, will review the Company's business strategy and recent financial results during the Company's presentation on Wednesday, February 18 at 11:30 a.m. local time.


Attendance at the conference is by invitation only. Cardiac Science will offer a live audio webcast of its presentation, which may be accessed at the Company's website at An archived replay of the presentation will also be available following the live presentation and can be accessed at

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit

Forward Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's expectations regarding revenues for the fourth quarter and full year 2008, charges relating to the restructuring announced in this press release, and expectations regarding the impact of the restructuring on 2009 operating results. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2008. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

    For more information,
    Company Contact:                Investor Contact:    Media Contact:
    Mike Matysik                    Doug Sherk           Christopher Gale
    Cardiac Science Corporation     Jenifer Kirtland     EVC Group Inc.
    Senior Vice President and CFO   EVC Group Inc.       646.201.5431
    425.402.2009                    415.896.6820         203.570.4681


SOURCE Cardiac Science
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sudden Cardiac Death Rare in Young Athletes
2. Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared?
3. TV News Coverage Reports on InnerCools CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago
4. Worlds First Cardiac Adult Stem Cell Trial to Take Place in Louisville
5. iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
6. Cardiac Science Increases R&D Capacity With 3-year Syncroness Agreement
7. The Sudden Cardiac Arrest Association Shoots Straight for the Heart
8. Experts Urge Limits on Use of Cardiac CT Scans
9. Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug
10. Easing regulations does not mean lower quality of cardiac care
11. New stretchable electrodes created to study stresses on cardiac cells
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: